Marcel Andrée

Point-of-care bulk testing for SARS-CoV-2 by combining hybridization capture with improved colorimetric LAMP

Long COVID: major findings, mechanisms and recommendations

Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study

Immunopathology of multiple sclerosis

Molecular diagnostic tests to predict the risk of progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis patients

Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue

Hematopoietic mobilization

Human Coronaviruses and Other Respiratory Viruses: Underestimated Opportunistic Pathogens of the Central Nervous System?

Attenuation of Antibody Titers from 3 to 6 Months after the Second Dose of the BNT162b2 Vaccine Depends on Sex, with Age and Smoking Risk Factors for Lower Antibody Titers at 6 Months

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection

Persistence and pathogenesis of the neurotropic polyomavirus JC

Age-dependent Immune Response to the Biontech/Pfizer BNT162b2 Coronavirus Disease 2019 Vaccination

Extraction-free SARS-CoV-2 detection by rapid RT-qPCR universal for all primary respiratory materials

CD34+ progenitor cells mobilized by natalizumab are not a relevant reservoir for JC virus